Revista de Senologia y Patologia Mamaria最新文献

Transición al inglés de la Revista de Senología: en desacuerdo 《血清学杂志》英文翻译：不同意

IF 0.2

Revista de Senologia y Patologia Mamaria Pub Date : 2025-10-01 DOI: 10.1016/j.senol.2025.100728

Josep Asensi Pérez

引用次数: 0

Experiencia inicial en localización mamaria y axilar con semilla ferromagnética en la cirugía del cáncer de mama 在乳腺癌手术中使用铁磁种子定位乳腺和腋窝的初步经验

IF 0.2

Revista de Senologia y Patologia Mamaria Pub Date : 2025-10-01 DOI: 10.1016/j.senol.2025.100726

María Jezabel Fernández Carrión , Laura Jiménez Díaz , David Ortiz López , Desireé Armas Ojeda , Laura Alonso-Lamberti Rizo , Magali García Suárez , Manuela Elvira Merola , Joaquín Marchena Gómez

{"title":"Experiencia inicial en localización mamaria y axilar con semilla ferromagnética en la cirugía del cáncer de mama","authors":"María Jezabel Fernández Carrión , Laura Jiménez Díaz , David Ortiz López , Desireé Armas Ojeda , Laura Alonso-Lamberti Rizo , Magali García Suárez , Manuela Elvira Merola , Joaquín Marchena Gómez","doi":"10.1016/j.senol.2025.100726","DOIUrl":"10.1016/j.senol.2025.100726","url":null,"abstract":"<div><h3>Introduction</h3><div>Currently, there are localization methods with advantages over the wires. Our objective was to analyze the accuracy and safety of the Magseed® ferromagnetic seed for the localization of non-palpable tumors and axillary lymph nodes in breast cancer patients at our center.</div></div><div><h3>Methods</h3><div>A retrospective observational study from March 2021 to July 2022, which included patients who underwent breast cancer surgery at our institution in whom the Sentimag-Magseed® system (Endomag Ltd.) was used for localization of non-palpable tumors and clip-marked axillary lymph nodes.</div></div><div><h3>Results</h3><div>Magseed® was used in 111 patients, implanted in the breast in 88 (79.3%), in the axilla in 16 (14.4%), and in both breast and axilla in 7 (6.3%). Tumors, marked lymph nodes, and seeds were successfully excised in all cases. In 2 patients (2%), tumor localization required wire (identification rate (IR): 98%). In one case, there was a failure to implant the seed in the tumor (1%). In the axilla, in 2 cases (7%) the seed was in the periganglionic fat. The lymph node IR was 100%. Ten patients (11%) had positive margins. Eight patients (8%) experienced complications unrelated to seed use. There was no operative mortality and no recurrences.</div></div><div><h3>Conclusions</h3><div>The use of the Magseed® seed for the localization of non-palpable tumors and axillary lymph nodes is a safe, reliable, and reproducible method. Studies are needed to assess its long-term results.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100726"},"PeriodicalIF":0.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145265255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Angiosarcoma de mama radioinducido de alto grado: ¿una patología cada vez más incidente? 高水平的放射诱发乳房血管肉瘤：一种越来越常见的病理？

IF 0.2

Revista de Senologia y Patologia Mamaria Pub Date : 2025-09-23 DOI: 10.1016/j.senol.2025.100723

Marta Yagüe Medina, Patricia López Arribas, Elena Martínez Gómez

引用次数: 0

Sarcoma pleomórfico indiferenciado de alto grado como tumor primario de mama en una paciente de 12 años: reporte de caso 12岁患者原发性乳腺瘤的高层次无区别多形性肉瘤：病例报告

IF 0.3

Revista de Senologia y Patologia Mamaria Pub Date : 2025-06-28 DOI: 10.1016/j.senol.2025.100709

Daniela María Cuadrado Franco, Sandra Milena Pantoja Burbano, Natalia Restrepo Abisambra

{"title":"Sarcoma pleomórfico indiferenciado de alto grado como tumor primario de mama en una paciente de 12 años: reporte de caso","authors":"Daniela María Cuadrado Franco, Sandra Milena Pantoja Burbano, Natalia Restrepo Abisambra","doi":"10.1016/j.senol.2025.100709","DOIUrl":"10.1016/j.senol.2025.100709","url":null,"abstract":"<div><div>High-grade undifferentiated pleomorphic sarcoma (UPS) of the breast is an extremely rare entity in children, representing less than 1% of malignant breast tumors. It poses a challenge in diagnosis and treatment due to the lack of specific guidelines. We describe the case of a 12-year-old patient with no significant medical history who presented to a tertiary care hospital with a rapidly growing, painful breast mass with cutaneous changes. Imaging studies showed a complex BIRADS 4C mass with no sign of metastasis. The case was submitted to a multidisciplinary board, which indicated primary surgical management. The postoperative pathology report indicated UPS. Adjuvant intensity-modulated radiation therapy (IMRT) and chemotherapy with ifosfamide and doxorubicin were indicated according to the protocol for pediatric non-rhabdomyosarcoma. The patient showed a favorable postoperative outcome, with complete graft healing and no signs of relapse to date. This case highlights the importance of aggressive surgical management and personalized adjuvant treatment in pediatric breast sarcomas, emphasizing the need for additional studies to establish specific management guidelines and optimize outcomes in this population.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100709"},"PeriodicalIF":0.3,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic implications of antiangiogenic agents and poly-adenosine diphosphate ribose polymerase (PARP) inhibitors in breast cancer: Current status and future perspectives 抗血管生成药物和多腺苷二磷酸核糖聚合酶（PARP）抑制剂在乳腺癌中的治疗意义：现状和未来展望

IF 0.3

Revista de Senologia y Patologia Mamaria Pub Date : 2025-06-26 DOI: 10.1016/j.senol.2024.100658

Muhammad Adil , Ghazanfar Abbas , Mavara Iqbal , Sarmad Rasheed , Shamsa Kanwal

{"title":"Therapeutic implications of antiangiogenic agents and poly-adenosine diphosphate ribose polymerase (PARP) inhibitors in breast cancer: Current status and future perspectives","authors":"Muhammad Adil , Ghazanfar Abbas , Mavara Iqbal , Sarmad Rasheed , Shamsa Kanwal","doi":"10.1016/j.senol.2024.100658","DOIUrl":"10.1016/j.senol.2024.100658","url":null,"abstract":"<div><div>Angiogenesis exhibits an integral role in cancer development and metastasis, therefore, antiangiogenic therapy forms the basis of several promising treatment strategies for breast cancer. Moreover, DNA damage has long been exploited in cancer chemotherapy and poly-adenosine diphosphate ribose polymerase (PARP) inhibitors constitute a novel group of drugs for the targeted disruption of DNA repair phenomenon attributed to breast cancer. Several antiangiogenic drugs and PARP inhibitors are effectively used as sole agents for the therapeutic management of early breast cancer and breast cancer gene mutation–induced breast cancer, respectively. Whereas, other antiangiogenic agents are employed for the ancillary therapy of metastatic breast cancer in conjunction with chemotherapeutic drugs. Likewise, some PARP inhibitors are recommended as adjuncts to chemotherapy against the triple-negative form of breast cancer. Combinations of PARP inhibitors with immunotherapy have also demonstrated favorable outcomes and offer an efficient treatment strategy for breast cancer. Currently, the combinations of antiangiogenic agents and PARP inhibitors are under investigation for prospective synergistic or additive effects in breast cancer. Despite being suggested for high-risk patients, the prophylactic use of PARP inhibitors has not been supported by means of preclinical or clinical studies. Finally, the identification of patient cohorts, determination of predictive biomarkers, optimization of dosing strategies, validation of long-term safety, and containment of resistance issues, necessitate proper attention for improving the clinical efficacy of potentially useful antiangiogenic agents and PARP inhibitors against breast cancer.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100658"},"PeriodicalIF":0.3,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synergistic effects of vitamin D3 and 5-aza-2′-deoxycytidine on VDR methylation and breast cancer progression 维生素D3和5-aza-2 ' -脱氧胞苷对VDR甲基化和乳腺癌进展的协同作用

IF 0.3

Revista de Senologia y Patologia Mamaria Pub Date : 2025-06-26 DOI: 10.1016/j.senol.2025.100708

Anjali K. Ravi , Saradhadevi Muthukrishnan , S. Abirami , Gayathiri Gunasangkaran , Vijaya Anand Arumugam , Velayuthaprabhu Shanmugam , Marie Arockianathan Pushpam , Ashokkumar Kaliyaperumal

{"title":"Synergistic effects of vitamin D3 and 5-aza-2′-deoxycytidine on VDR methylation and breast cancer progression","authors":"Anjali K. Ravi , Saradhadevi Muthukrishnan , S. Abirami , Gayathiri Gunasangkaran , Vijaya Anand Arumugam , Velayuthaprabhu Shanmugam , Marie Arockianathan Pushpam , Ashokkumar Kaliyaperumal","doi":"10.1016/j.senol.2025.100708","DOIUrl":"10.1016/j.senol.2025.100708","url":null,"abstract":"<div><h3>Introduction</h3><div>Breast cancer (BC) is a highly aggressive disease with limited treatment options. Calcitriol, the active form of vitamin D3, exerts anticancer effects via the vitamin D receptor (VDR), but its efficacy is often reduced by VDR promoter hypermethylation. This study investigates the role of VDR promoter hypermethylation in breast cancer and evaluates the potential of 5-Aza-2dC and vitamin D3 to restore VDR function and enhance therapeutic efficacy.</div></div><div><h3>Methods</h3><div>BALB/c mice were treated with DMBA to induce VDR promoter hypermethylation. The effects of 5-Aza-2dC and Vitamin D3 on VDR, CYP27B1, and CYP24A1 expression were evaluated to assess their impact on calcitriol signaling and BC proliferation.</div></div><div><h3>Results</h3><div>DMBA-treated mice exhibited VDR hypermethylation, increased CYP24A1, and decreased VDR and CYP27B1 expression, with significantly enhanced tumor growth. Treatment with 5-Aza-2dC reversed VDR hypermethylation, restored VDR and CYP27B1 expression, and suppressed CYP24A1, leading to reduced tumor size and higher vitamin D3 levels. Vitamin D3 pre-treatment preserved VDR and CYP27B1 expression, reduced CYP24A1, and protected against VDR methylation, decreasing tumor proliferation. Combined treatment with 5-Aza-2dC and vitamin D3 synergistically enhanced VDR demethylation, reduced CYP24A1, increased vitamin D3 levels, and significantly inhibited BC proliferation, reducing tumor size.</div></div><div><h3>Conclusion</h3><div>Reversing VDR hypermethylation with 5-Aza-2dC and vitamin D3 offers a promising strategy to overcome calcitriol resistance and improve therapeutic outcomes in BC. This combination may enhance the efficacy of vitamin D3-based therapies in BC treatment.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100708"},"PeriodicalIF":0.3,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144489680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sensitivity and specificity of MammaTyper® versus immunohistochemistry in the molecular subtyping of breast cancer: The SUBMARIN study MammaTyper®与免疫组织化学在乳腺癌分子分型中的敏感性和特异性：SUBMARIN研究

IF 0.3

Revista de Senologia y Patologia Mamaria Pub Date : 2025-06-19 DOI: 10.1016/j.senol.2025.100706

Laia Bernet-Vegué , Stella Peláez Malagón , Marina Berna Rubio

{"title":"Sensitivity and specificity of MammaTyper® versus immunohistochemistry in the molecular subtyping of breast cancer: The SUBMARIN study","authors":"Laia Bernet-Vegué , Stella Peláez Malagón , Marina Berna Rubio","doi":"10.1016/j.senol.2025.100706","DOIUrl":"10.1016/j.senol.2025.100706","url":null,"abstract":"<div><h3>Introduction</h3><div>Immunohistochemical study for oestrogen receptor (ER/<em>ESR1</em>), progesterone receptor (PR/<em>PGR</em>), human epidermal growth factor receptor 2 (HER2/<em>ERBB2</em>), and proliferation marker Ki-67/<em>MKI67</em>PR is the standard technique for diagnosing the molecular subtype in clinical practice. However, less subjective techniques, such as the mRNA-quantifying MammaTyper® (MMT), are needed.</div></div><div><h3>Materials and methods</h3><div>Observational, retrospective, single-centre study carried out at the Vinalopó University Hospital, Alacant, Spain, with 109 consecutive formalin-fixed paraffin-embedded samples coming from infiltrating breast carcinoma diagnosed between 2022 and 2023.</div></div><div><h3>Results</h3><div>The global concordance of MMT with IHC was 76.15%. MMT results were concordant with IHC in all HER2-positive (4, 100%) or HER2-Luminal B samples (11, 100%), in 45 (95.7%) classified as Luminal B-like (HER2–) and in 11 (84.6%) Triple negative. MMT disagreed on 22 (64.7%) Luminal A-like samples, mainly because MMT detected Ki-67 expression. High values of positive agreement for ER (96.3%, 95% CI: 90.9; 98.6%), PR (89.9%, 95% CI: 82.8; 94.3%), and HER2 (87.0%, 95% CI: 67.9; 95.5%) were obtained. MMT detected more positives than IHC for Ki-67 (52.6%, 95% CI: 43.2; 62.0%) and HER2-low (74.3%, 95% CI: 66.1; 82.5%).</div></div><div><h3>Conclusion</h3><div>The concordance between both techniques was high for ER, PR, and HER2. Notably, MMT standardises the identification of Luminal A-B-like and HER2-low thanks to its higher sensitivity towards HER2 and Ki-67.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100706"},"PeriodicalIF":0.3,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144321885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into breast cancer education concerning knowledge, awareness, and perceptions: A cross-sectional study among young adult girls 关于乳腺癌知识、意识和观念教育的见解：一项对年轻成年女孩的横断面研究

IF 0.3

Revista de Senologia y Patologia Mamaria Pub Date : 2025-06-17 DOI: 10.1016/j.senol.2025.100707

Anmar Al-Taie , Ali N. Hussein , Asma K. Allah

{"title":"Insights into breast cancer education concerning knowledge, awareness, and perceptions: A cross-sectional study among young adult girls","authors":"Anmar Al-Taie , Ali N. Hussein , Asma K. Allah","doi":"10.1016/j.senol.2025.100707","DOIUrl":"10.1016/j.senol.2025.100707","url":null,"abstract":"<div><h3>Introduction</h3><div>In developing countries, mortality from breast cancer (BC) is higher due to changes in lifestyle that produce a rise in incidence, with over half of patients receiving advanced-stage diagnoses. Young girls have a significant impact on women's knowledge and awareness of BC in their communities and their motivation needs to be evaluated.</div></div><div><h3>Objective</h3><div>The aim of this study was to assess the level of knowledge of BC regarding potential risk factors, awareness about the most common warning signs, diagnostic and screening, and perceptions towards BC treatment outcomes among young adult girls in Northern Cyprus.</div></div><div><h3>Methods</h3><div>A cross-sectional, observational study was conducted among young adult girls in three major provinces of Northern Cyprus: Nicosia, Kyrenia, and Famagusta, using a structured, validated questionnaire with five parts.</div></div><div><h3>Results</h3><div>A total of 300 young adult girls were enrolled in this study, with a mean age of 22.37 years. There was a significant lack of knowledge about BC risk factors and diagnosis (score = 8.4, <em>P</em> < 0.0001); (score = 5.7, <em>P</em> < 0.0001, respectively). There was also a significant lack of awareness of the BC signs (score = 6.6, <em>P</em> < 0.0001), and perceptions towards treatment (score = 5.3, <em>P</em> < 0.0001).</div></div><div><h3>Conclusion</h3><div>This study found that most young adult girls in Northern Cyprus had lower than expected knowledge of BC risk factors, warning signs, and early cancer diagnosis and screening. The study population, on the other hand, had fairly positive perceptions of BC management.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 4","pages":"Article 100707"},"PeriodicalIF":0.3,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144297580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precision paradigm in breast cancer management: A mini review 乳腺癌管理的精确范式：一个小回顾

IF 0.3

Revista de Senologia y Patologia Mamaria Pub Date : 2025-05-29 DOI: 10.1016/j.senol.2025.100703

Suman Bhadra , Sohini Kulavi , Jaya Bandyopadhyay

{"title":"Precision paradigm in breast cancer management: A mini review","authors":"Suman Bhadra , Sohini Kulavi , Jaya Bandyopadhyay","doi":"10.1016/j.senol.2025.100703","DOIUrl":"10.1016/j.senol.2025.100703","url":null,"abstract":"<div><div>“One-size-fits-all” is a conventional medical approach to treating patients with similar symptoms with similar types of drugs. The effectiveness of various targeted therapies in such diverse tumors has entered an era in which treatment is determined based on the tumor's molecular abnormality profile, or “characteristics,” rather than on the type of tumor tissue or the site of anatomical origin. It improves the prognosis of patients and determines their quality of life. The evolving field of personalized medicinal drugs has significant potential in cancer prevention, diagnosis, and therapeutics. Identifying cancer susceptibility genes, such as the BRCA gene in breast cancer, helps screening programs identify patients at risk for developing cancer and make decisions about individual risk-modifying behaviors. Precision medicine plays a vital role in breast cancer management, e.g., using intracellular agents (Vemurafenib and Olaparib) and monoclonal antibodies (Cetuximab and Trastuzumab) in HER2-positive breast cancer. This review mainly focuses on the role of precision medicine in preventing and treating breast cancer.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100703"},"PeriodicalIF":0.3,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144168837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Journal of Senology and Breast Disease. Why Transition to English? 老年病学与乳腺疾病杂志。为什么要过渡到英语？

IF 0.3

Revista de Senologia y Patologia Mamaria Pub Date : 2025-05-26 DOI: 10.1016/j.senol.2025.100705

David Martínez Ramos

引用次数: 0